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Abstract
Background: According to the traditional tuberculosis (TB) treatment paradigm, the initial doses of treatment
rapidly kill most Mycobacterium tuberculosis (Mtb) bacilli in sputum, yet many more months of daily treatment are
required to eliminate a small, residual subpopulation of drug-tolerant bacilli. This paradigm has recently been
challenged following the discovery that up to 90% of Mtb bacilli in sputum are culturable only with growth-factor
supplementation. These “differentially culturable” bacilli are hypothesized to be more drug-tolerant than routinely
culturable bacilli. This hypothesis implies an alternative paradigm in which TB treatment does not rapidly reduce
the total Mtb population but only the small, routinely culturable subpopulation. To evaluate these competing
paradigms, we developed a culture-independent method for quantifying the viable fraction of Mtb bacilli in sputum
during treatment.
Methods: We used GeneXpert MTB/RIF to quantify Mtb DNA in sputa collected longitudinally from Ugandan adults
taking standard 4-drug treatment for drug-susceptible pulmonary TB. We modeled GeneXpert cycle thresholds over
time using nonlinear mixed-effects regression. We adjusted these models for clearance of DNA from killed-but-not-
yet-degraded bacilli, assuming clearance half-lives ranging from 0 to 1.25 days. We used a convolution integral to
quantify DNA from viable bacilli only, and converted cycle thresholds to Mtb genomic equivalents. We replicated
our results in a South African cohort.
Results: We enrolled 41 TB patients in Uganda. Assuming a DNA-clearance half-life of 0 days, genomic equivalents
of viable sputum bacilli decreased by 0.22 log/day until 8.8 days, then by 0.07 log/day afterwards. Assuming a DNA-
clearance half-life of 1.25 days, genomic equivalents of viable bacilli decreased by 0.36 log/day until 5.0 days, then
by 0.06 log/day afterwards. By day 7, viable Mtb had decreased by 97.2–98.8%. We found similar results for 19 TB
patients in South Africa.
Discussion: Using a culture-independent method, we found that TB treatment rapidly eliminates most viable Mtb
in sputum. These findings are incompatible with the hypothesis that differentially culturable bacilli are drug-tolerant.
(Continued on next page)
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Conclusions: A culture-independent method for measuring viable Mtb in sputum during treatment corroborates
the traditional TB treatment paradigm in which a rapid bactericidal phase precedes slow, elimination of a small,
residual bacillary subpopulation.
Keywords: Tuberculosis, Mycobacterium tuberculosis, Treatment, Sputum, Drug tolerance, Differentially culturable
Background
Traditional understanding of tuberculosis (TB) treat-
ment has recently been challenged by reports that up to
90% of Mtb in the sputum of treatment-naïve patients
may be non-culturable on standard agar plates, growing
only with growth factor supplementation (“differentially
culturable”) [1–5]. The traditional TB treatment para-
digm is based on enumeration of Mycobacterium tuber-
culosis (Mtb) that grows on agar plates (routinely
culturable Mtb). This traditional measure of sputum ba-
cillary load suggests that killing is biphasic. The initial
5–7 day bactericidal phase appears to kill ~ 99% of Mtb
in sputum [6–8]. During the subsequent, “sterilizing”
phase of treatment, the rate of killing appears to slow by
at least 80% [9]. The residual population is comprised of
drug-tolerant “persister” phenotypes that are capable of
surviving prolonged antibiotic exposure despite an ab-
sence of drug-resistance mutations [10, 11]. Critically,
the traditional biphasic killing paradigm hinges on the
assumption that enumeration of routinely culturable
Mtb accurately represents killing in the total Mtb popu-
lation of sputum (i.e., it does not account for an add-
itional, differentially culturable, component of sputum).
The discovery of differentially culturable Mtb has raised
concern that the traditional paradigm may be based on an
incomplete and potentially misleading measure of Mtb
burden. The differentially culturable Mtb population is
particularly important if it responds to treatment differ-
ently than routinely culturable Mtb. Recent in vitro evi-
dence suggests differentially culturable Mtb may be more
drug tolerant than routinely culturable Mtb [3, 12]. This
hypothesis implies an alternative paradigm in which
drug-tolerant Mtb phenotypes dominate sputum even
prior to TB treatment [1]. This paradigm suggests that
treatment does not rapidly decrease the total burden of
Mtb in sputum; only the small routinely culturable frac-
tion is rapidly and selectively eliminated [13]. Validation
of this alternative paradigm would fundamentally reshape
our understanding of TB treatment and have critical im-
plications for drug development [13].
A key question is whether the hypothesized drug toler-
ance of differentially culturable Mtb has practical signifi-
cance in patients with TB. Specifically, are differentially
culturable Mtb phenotypes sufficiently drug tolerant in
vivo that the traditional biphasic killing paradigm should
be questioned? For the traditional paradigm to remain
valid, routinely culturable and differentially culturable
Mtb would have to be killed at roughly similar rates. By
contrast, if differentially culturable Mtb are killed much
more slowly, enumeration of only routinely culturable
Mtb would misrepresent change in the total Mtb burden
of sputum. This would favor the alternative paradigm that
the total Mtb burden of sputum does not decrease rapidly.
To re-evaluate these paradigms in a culture-independent
manner, we developed a new approach to characterizing
the rates and phases of Mtb killing during treatment for ac-
tive TB based on Mtb DNA abundance in sputum. Quanti-
fication of Mtb DNA enumerates the total Mtb population
(irrespective of whether bacilli are routinely culturable or
differentially culturable). Using a conceptually simple math-
ematical model, we adjust our estimates of the quantity of
Mtb for the characteristic of DNA that is often cited as lim-
iting its usefulness as a measure of treatment response – its
slow degradation after cell death [14]. Our analysis does
not address what proportion of Mtb in sputum is differen-
tially culturable; instead we sought evidence that the differ-
entially culturable Mtb population is cleared from sputum
substantially more slowly than routinely culturable Mtb.
The resulting culture-independent estimates of early killing
support the traditional biphasic killing paradigm [6–8].
Methods
Study design and enrollment
Our primary analysis enrolled consecutive adults hospi-
talized with drug-susceptible pulmonary TB at Mulago
National Referral Hospital in Kampala, Uganda as previ-
ously described [15]. Patients provided sputa and a
NALC-NaOH processed pellet was treated with sample
reagent and tested with GeneXpert MTB/RIF (Version
G4, Cepheid, Sunnyvale, CA USA) testing before treat-
ment (day 0) and after 2, 4, 7, 14, 28 and 56 daily stand-
ard doses of isoniazid, rifampicin, pyrazinamide, and
ethambutol. To determine whether our results were re-
producible, we selected a previously-published study in
South Africa as a replication cohort. The South African
study evaluated the effect of pre-treatment with propi-
dium monoazide (PMA) on GeneXpert MTB/RIF (also
Version G4) [16]. Our analysis used only data from 19
patients with non-PMA treated (control) samples ob-
tained at day 0 and after 3, 7, 14, 28, 35, and 56 days of
treatment.
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Conceptual basis for using DNA to estimate viable Mtb
Before treatment, the burden of Mtb DNA in sputum
predominantly reflects the burden of viable bacilli. Dur-
ing treatment, measured DNA has two components:
DNA from viable Mtb and residual DNA from dead
Mtb. We aimed to estimate the viable and dead compo-
nents. We defined the half-life of DNA clearance as days
required for a 50% reduction in DNA from dead Mtb,
due to either expectoration or degradation by active host
processes. For any DNA burden at any time point, the
longer the DNA clearance half-life is, the larger the dead
component and the smaller the viable component must
be. Using this construct and assuming a range of plaus-
ible clearance rates, we estimated the burden of viable
Mtb over time.
Analysis
We modeled mean cycle-threshold (CT) values for Gen-
eXpert during the first 56 days of treatment using a non-
linear mixed-effects model framework. Conceptually,
mean cycle threshold is inversely proportional to the loga-
rithm of the number of DNA copies. Therefore we mod-
eled CT values as a linear function of the logarithm of the
total DNA (viable + dead) at time t (See Additional file 1
for details). We assumed that the viable component of
DNA in sputum decreased exponentially with treatment,
and allowed the rate of decrease in DNA to change from a
higher to a lower rate at a single time point; this change
point was not pre-specified, but rather was estimated as a
parameter in the model. We used a convolution integral
to solve for the component of non-degraded DNA from
dead bacteria at a given time t. We evaluated five possible
DNA clearance half-lives: zero, 0.5, 0.75, 1, and 1.25 days.
A clearance half-life of zero days represents the ex-
treme and unrealistic assumption that DNA from dead
Mtb is degraded instantaneously, implying that all Mtb
DNA originates from viable bacilli. We used a
likelihood-based approach assuming a Gaussian distri-
bution to account for right censoring of Xpert CT
values at 41 cycles. In addition, our models included a
random intercept for each subject to account for cor-
relation due to repeated measures made on subjects
over time. Our base models assumed that, prior to
treatment, 99% of Mtb DNA in sputum arose from liv-
ing bacteria. In sensitivity analyses, we fit alternative
models in which 80% or 90% of Mtb in treatment-naïve
sputum was assumed to be viable. We fit all models in
SAS 9.3 Proc NLMIXED.
Conversion of GeneXpert MTB/RIF to genomic equivalents
For the purposes of conceptual illustration only, we
converted estimated CT values from our models to a
measure of bacillary burden (“genomic equivalents”)
based on the data previously presented by Blakemore
et al. showing a linear relationship between log10 Mtb
and Xpert CT values [17].
Results
For our primary analysis, 41 Ugandan adults with
drug-susceptible, culture-positive pulmonary TB were
enrolled. Twenty-three (56%) were persons living with
HIV. The proportion with a positive sputum Xpert result
declined gradually, from 100% at baseline to 80% at four
weeks to 50% at eight weeks. The previously-published
replication cohort included 19 South African patients
with drug-susceptible TB and serial Xpert testing per-
formed without PMA pre-treatment [16].
With the half-life of DNA clearance assumed to be
zero, the viable component of Mtb DNA in sputum ini-
tially decreased rapidly (− 0.22 log/day) among Ugandan
patients. There was a change point at 8.8 days, after
which the rate of decline slowed to − 0.07 log/day (Fig. 1
& Table 1). Even in this extreme case that assumed no
dead component, viable Mtb decreased 97.2% from base-
line to day 7. With more plausible estimates for the
half-life of Mtb DNA clearance, the initial rate of killing
was faster and the change point occurred earlier. For ex-
ample, with a DNA clearance half-life of 1.25 days, the
initial rate of killing was − 0.36 log/day) and the change
point was 5.0 days. When the half-life was extended to
1.5 days, the model estimated no viable component at
7 days, inconsistent with the positive culture results ob-
tained from each individual. The rate of killing was
69.4–82.2% slower in the later killing period relative to
the early killing period. With each increase in the
half-life of DNA clearance, the differences between the
rates in the early and late periods increased.
In our replication cohort (19 South African patients),
we also identified a biphasic pattern. With a clearance
half-life of zero, the viable component decreased 92.1%
(95% CI: 65.1–98.2%) by day 7. There was a significant
change point at 17.3 days by which time the viable com-
ponent had decreased 99.8% (95% CI: 93.8–100%). The
number of observations was insufficient to fit models es-
timating the components of living bacilli and dead bacilli
using half-life parameters.
Discussion
Our analysis identified a sharp decline in the burden of vi-
able Mtb DNA during the first days of standard TB treat-
ment. This finding is incompatible with the hypothesis
that pre-treatment sputum is dominated by drug-tolerant
phenotypes and that only a small proportion of Mtb is
killed rapidly during initial TB treatment. Since the total
Mtb burden is rapidly reduced, we conclude that the
differentially culturable fraction could not have a clinicall-
y-significant degree of drug tolerance. Put simply, a rapid
decrease in Mtb DNA in sputum must indicate rapid
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killing, regardless of whether the bacteria routinely or dif-
ferentially culturable.
Our analysis did not estimate what proportion of Mtb
is differentially culturable. Rather we asked whether
there is evidence in humans that differentially culturable
Mtb is drug-tolerant to a degree that threatens the valid-
ity of the traditional culture-based biphasic paradigm of
killing. The rapid clearance of total Mtb we observed
suggests that the population of Mtb present at baseline
could not be dominated by highly tolerant phenotypes.
Our results do not imply that drug-tolerant phenotypes
are absent from pre-treatment sputum. Instead, our ana-
lysis is consistent with the prevailing hypothesis that
only a small fraction of Mtb in sputum is in a
drug-tolerant phenotype at baseline.
The rapid initial decline in DNA we observe is consistent
with declines observed with other culture-independent
measures of bacterial burden, namely messenger RNA
(mRNA) and ribosomal RNA (rRNA). For example, both
our previous study [15] and another [18] found that
Mtb mRNA abundance in sputum decreases > 99% by
the fourth day of treatment. Among South African
patients, Honeyborne et al. described an 88% reduc-
tion in Mtb 16S rRNA during the first three days of
treatment [1]. Although slow-growing, drug-tolerant
phenotypes likely have lower mRNA or rRNA content
per viable bacillus than rapidly-killed phenotypes [19],
the consistency of these changes in mRNA, rRNA
and DNA with the changes observed in historical,
culture-based studies reinforces the current finding
that the differentially culturable fraction of sputum
must not be highly drug-tolerant at baseline.
Our analysis has several limitations. First, there is un-
certainty around our assumption that 99% of DNA is
from viable Mtb prior to treatment. In sensitivity ana-
lyses described in Additional file 2, we tested other as-
sumptions (e.g., prior to treatment 80% or 90% of DNA
is from viable Mtb); these assumptions had minimal im-
pact on our conclusions. Second, the actual half-life of
DNA clearance is unknown and may also vary from pa-
tient to patient. Our models therefore evaluated a
spectrum of possible half-lives, ranging from zero days
(i.e., instantaneous degradation) to 1.25 days. Since we
observed an average decline of 1.56 log DNA by day 7,
the hypothetical upper bound of average DNA clearance
half-life is 1.4 day (calculated by assuming that all Mtb is
dead at baseline). Our DNA clearance half-life assump-
tions are compatible with the observation that patients
may remain sputum Xpert positive well after treatment
completion since many DNA clearance half-lives pass
before Xpert MTB/RIF turns negative [14]. Finally, Xpert
MTB/RIF CT values are not validated for quantification
[20]. We therefore confirmed Xpert MTB/RIF results by
measuring DNA abundance and rate of decline in longi-
tudinal specimens in a subset (n = 17) of these patients
using a validated qRT-PCR assay [15]. Models fit to
qRT-PCR data recapitulated results based on Xpert
MTB/RIF.
Our study also had several strengths. First, our approach
enabled us to make culture-independent estimates of
Fig. 1 Estimated viable Mtb in sputum during the first 56 days of treatment for drug-susceptible TB among 41 Ugandan adults based on
GeneXpert data. Models assumed different rates of clearance of DNA from dead Mtb ranging from instantaneous (black) to 0.5 days (blue) to
0.75 days (green), 1 day (orange), to 1.25 days (red)
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change in viable Mtb during treatment. The advantage is
that this analysis is agnostic to the question of differential
versus routine culturability. Recent identification of differ-
entially culturable Mtb [1–5] has provided insights into
heterogeneous Mtb populations but the implications of
differentially culturable Mtb for patients and treatment
paradigms has remained unclear. Our analysis suggests
that – in patients – differentially culturable Mtb are un-
likely to be killed much more slowly than routinely cultur-
able Mtb. Second, we evaluated these insights in a second
and distinct study population from South Africa collected
by a different group of investigators, which increases the
generalizability of our findings. Finally, we used rigorous
methods to maximize the accuracy of quantification and
frequently repeated sputum collection.
Conclusions
Our culture-independent analysis supports the traditional
paradigm that TB treatment involves a short bactericidal
phase in which most Mtb bacilli are rapidly killed followed
a prolonged sterilizing phase in which minority subpopula-
tions of drug-tolerant phenotypes are slowly eliminated.
Our results are not consistent with the recently-proposed
alternative hypothesis, namely that most of the Mtb popula-
tion of sputum from treatment-naïve patients is tolerant of
and refractory to antimicrobial treatment at baseline. Rou-
tine culture on agar plates may fail to enumerate a signifi-
cant fraction of the bacterial population, but the
differentially culturable Mtb population does not appear to
be highly drug-tolerant. Our analysis corroborates the long-
standing conceptual model of drug-dependent Mtb killing.
Confirming the correct model of killing is critically import-
ant to the global community’ efforts to expand the pipeline
of new drug regimens for Mtb.
Additional files
Additional file 1: Technical appendix. A methods supplement providing
technical details of the model. (PDF 197 kb)
Additional file 2: Table S1. This is a supplemental table providing
model outputs based on alternative assumptions that 80% or 90% of Mtb
DNA in sputum prior to treatment initiation originates from viable bacilli.
(DOCX 16 kb)
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